MRNA Earnings Date: Nov 6, 2026 (Estimated) — Moderna, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is MRNA's next earnings date?
Moderna, Inc. (MRNA) is expected to report Q3 2026 earnings on Friday, November 6, 2026 at 6:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$1.10 on revenue of $890.3M.
How did MRNA do in its last earnings report?
In its most recent report on Jul 31, 2026 (Q2 2026), Moderna, Inc. posted EPS of -$1.97 versus the -$2.07 estimate, a beat of 4.8%. Revenue was $145.0M against a $104.4M estimate. The stock's 1-day post-earnings move was -5.4%.
How much does MRNA stock move after earnings?
MRNA beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 4.2% (up or down) in the day after earnings.
About Moderna, Inc.
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-31 | Q2 2026 | -2.07 | -1.97 | +4.83% | $145.0M | ✅ Beat | -5.35% | -7.01% | +138.24% |
| 2026-05-01 | Q1 2026 | -3.71 | -1.18 | +68.19% | $389.0M | ✅ Beat | -1.24% | +5.66% | +0.26% |
| 2026-02-13 | Q4 2025 | -2.60 | -2.11 | +18.85% | $678.0M | ✅ Beat | +5.29% | +24.33% | +32.91% |
| 2025-11-06 | Q3 2025 | -2.17 | -0.51 | +76.50% | $1.02B | ✅ Beat | +3.27% | +13.37% | +17.57% |
| 2025-08-01 | Q2 2025 | -2.98 | -2.13 | +28.52% | $142.0M | ✅ Beat | -6.61% | -9.98% | -18.50% |
| 2025-05-01 | Q1 2025 | -3.18 | -2.52 | +20.75% | $108.0M | ✅ Beat | -5.29% | -15.70% | -6.94% |
| 2025-02-14 | Q4 2024 | -2.68 | -2.91 | -8.58% | $966.0M | ❌ Miss | +3.35% | +11.31% | +8.74% |
| 2024-11-07 | Q3 2024 | -1.90 | 0.03 | +101.58% | $1.86B | ✅ Beat | -2.95% | -18.66% | -14.23% |
Showing last 8 quarters.
Revenue by segment & region
By region
Q2 FY26 · $94.0M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 74.5% | $70.0M | -20.5% | $308.0M | $31.0M | $88.0M | $782.0M |
| Europe | 17.0% | $16.0M | — | $317.0M | — | — | $16.0M |
| Rest Of The World | 8.5% | $8.0M | -69.2% | $397.0M | $55.0M | $26.0M | $175.0M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.